Modelling COVID-19 transmission in the United States through interstate and foreign travels and evaluating impact of governmental public health interventions.

: The first case of COVID-19 was reported in Wuhan, China in December 2019. The disease has spread to 210 countries and has been labelled as a pandemic by the World Health Organization (WHO). Modelling, evaluating, and predicting the rate of disease transmission is crucial in understanding optimal methods for prevention and control.

Modelling the impact of plasma therapy and immunotherapy for recovery of COVID-19 infected individuals.

Since the first case of COVID-19 was detected in Wuhan, China in December 2019, COVID-19 has become a pandemic causing a global economic and public health emergency. There is no known treatment or vaccine available for COVID-19 during the initial period of the outbreak. Immunotherapy and plasma therapy has been used with satisfactory efficacy over the past two decades in many viral infections like SARS (Systemic Acute Respiratory Syndrome), MERS (Middle East Respiratory Syndrome) and H1N1.

Optimal control of HCV transmission under liquoring.

Chronic hepatitis C virus (HCV) and alcohol are common causes of chronic liver diseases and both are recognized as major causes of liver disease worldwide. Each poses a major public and economic burden to society, and when the two co-exist they appear to have a synergistic effect in the progression of chronic liver disease. In this research, we developed a SIRS model of transmission of the hepatitis C virus (HCV) under effect of liquoring in six compartments: Susceptible, Low liquoring, High liquoring, Acute, Chronic and Recovered Individuals.